Biomed Industries to Advance NA-931 Into Two Global Phase 3 Trials as Monotherapy and in Combination With Semaglutide and Tirzepatide for Obesity Advancing NA-931 into two Phase 3 programs as ...
The shares of Panacea Biotec touched its 52-week high of ₹581 on May 15, 2025, and a 52-week low of ₹282.15 on February 28, ...
The use of base editing to generate universal off-the-shelf CAR T cells induced durable remissions -- up to 36 months in one ...
Data readouts planned for CLN-978 across all three autoimmune indications in 2026, including single dose and repeat dosing data ...
As decentralized finance matures, the challenges facing sophisticated traders are beginning to resemble those of traditional ...
AtaiBeckley Inc (NASDAQ: ATAI) (“AtaiBeckley” or the “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient ...
The Print on MSN
India’s first dengue vaccine has been in the making for 17 yrs. DengiAll has the world excited
At the Panacea Biotec office, conversations around DengiAll are cloaked with an air of eagerness. With the human trials ...
Follow live updates as developments emerge on Venezuela's future and U.S. allies respond to Trump's threats against Greenland ...
This is the significant policy signal. Over the past few years, there have been several trade facilitation initiatives. Yet, ...
MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License ...
This clinical-stage biotech focused on precision medicines reported significant insider selling, according to recent SEC filings.
The FDA and European Medicines Agency (EMA) have awarded orphan drug designation to CPI-008 (cRGD-ZW800-1), a novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback